PRKACG Antibody

Code CSB-PA018690LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human liver cancer using CSB-PA018690LA01HU at dilution of 1:100

  • Western Blot
    Positive WB detected in: Hela whole cell lysate, HepG2 whole cell lysate
    All lanes: PRKACG antibody at 3.2μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 41 kDa
    Observed band size: 41 kDa

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) PRKACG Polyclonal antibody
Uniprot No.
Target Names
PRKACG
Alternative Names
cAMP-dependent protein kinase catalytic subunit gamma antibody; KAPCG_HUMAN antibody; KAPG antibody; PKA C gamma antibody; PKA C-gamma antibody; PKACg antibody; PRKACG antibody; Protein kinase cAMP dependent catalytic gamma antibody; Serine (threonine) protein kinase antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human cAMP-dependent protein kinase catalytic subunit gamma protein (1-43AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The PRKACG Antibody (Product code: CSB-PA018690LA01HU) is Non-conjugated. For PRKACG Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA018690LB01HU PRKACG Antibody, HRP conjugated ELISA
FITC CSB-PA018690LC01HU PRKACG Antibody, FITC conjugated
Biotin CSB-PA018690LD01HU PRKACG Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Phosphorylates a large number of substrates in the cytoplasm and the nucleus.
Gene References into Functions
  1. The missense p.74Ile>Met PRKACG mutation is associated with a marked defect in proplatelet formation and a low level in filamin A in megakaryocytes. PMID: 25061177
  2. PKA-mediated phosphorylation of GPIbbeta at Ser(166) negatively regulates VWF binding to GPIb-IX and is one of the mechanisms by which PKA mediates platelet inhibition PMID: 12361948
  3. Results suggest that Cgamma and Calpha differ in structure and function in vitro, supporting the hypothesis that functionally different C-subunit isozymes could affect cAMP signal transduction downstream of protein kinase A activation. PMID: 15039079
Involvement in disease
Bleeding disorder, platelet-type 19 (BDPLT19)
Protein Families
Protein kinase superfamily, AGC Ser/Thr protein kinase family, cAMP subfamily
Tissue Specificity
Testis specific. But important tissues such as brain and ovary have not been analyzed for the content of transcript.
Database Links

HGNC: 9382

OMIM: 176893

KEGG: hsa:5568

STRING: 9606.ENSP00000366488

UniGene: Hs.158029

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*